Kala Bio signs non-binding LOI to buy telehealth platform for about $15 million

Kala Bio signed a non-binding LOI to buy a privately held MSO with a 50-state telehealth platform in a deal valued at about $15 million, payable in cash and Kala stock. Due diligence runs 45 days and is expected to end in November 2026, with closing targeted for late 2026 or early 2027.